Regeneron’s REGN-COV2 Demonstrate Reduction in Viral Load and Improve Symptoms in Non-Hospitalized Patients with COVID-19

 Regeneron’s REGN-COV2 Demonstrate Reduction in Viral Load and Improve Symptoms in Non-Hospitalized Patients with COVID-19

Regeneron’s REGN-COV2 Demonstrate Reduction in Viral Load and Improve Symptoms in Non-Hospitalized Patients with COVID-19

Shots:

  • Regeneron reports first data of seamless P-I/II/III study assessing REGN-COV2 that demonstrated a reduction in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. It also reduces the medical visit
  • The descriptive analysis assesses REGN-COV2 (8gm/ 2.4gm) vs PBO in the first 275 patients enrolled in the trial in a ratio (1:1:1).  The trial suggested that REGN-COV2 could help patients whose own immune system is not strong enough to combat the virus
  • In seronegative patients, the median time to symptom relief is (8/6days vs 13days), rapid reduction in viral load. Regeneron believes its dual-antibody formula will limit the ability of the virus to escape detection and attack

Click here ­to­ read full press release/ article | Ref: Regeneron | Image: Asia News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post